1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Dermapharm Holding SE

Dermapharm Holding SE

DMPHF
Dermapharm Holding SEUS flagOther OTC
39.56
USD
- -
- -
1.96BMarket Cap
Dermapharm Holding SE
DMPHF
(Other OTC)

Recent

price

39.56

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
7.27
7.15
8.9
9.35
10.72
13.02
14.74
17.51
19.03
21.09
21.93
21.59
Revenue per Share
- -
- -
0.24
1.54
1.56
1.41
1.43
1.59
3.89
2.49
1.16
2.11
2.16
Basic EPS, GAAP
- -
0.48
0.47
1.18
0.15
2.49
1.01
1.68
3.51
4.63
3.3
3.03
3.06
Free Cash Flow per Basic Share
- -
0.1
- -
- -
- -
- -
0.77
0.8
0.88
2.17
1.05
0.88
- -
Dividend per Share
- -
0.56
0.76
1.15
0.52
2.9
3.58
4.29
7.28
7.6
7.82
9.05
9.92
Book Value per Share
- -
-1.1
-0.74
-0.53
-1.69
0.22
-3.92
-4.44
-1.11
-0.81
-10.74
-8.92
-7.8
Tangible Book Value per Share
- -
54
54
50
50
53
54
54
54
54
54
54
54
Basic Weighted Avg Shares
- -
391
385
444
467
572
701
794
943
1,025
1,135
1,181
1,160
Sales/Revenue/Turnover
- -
11.3
17.58
19.33
19.44
18.87
17.08
18.3
30.44
23.62
15.86
18.19
18.51
Operating Margin (%)
- -
18
15
14
16
30
48
47
55
95
102
87
85
Depreciation Expense
- -
- -
13
77
78
75
77
86
210
134
62
114
116
Net Income, GAAP
- -
6.32
5.28
7.09
11.68
27.83
29.3
31.41
28.7
38.69
42.89
35.04
33.54
Effective Tax Rate (%)
- -
-0.02
3.3
17.32
16.64
13.16
11.01
10.81
22.23
13.1
5.49
9.64
10
Profit Margin (%)
13
72
81
42
112
225
251
267
364
316
236
267
351
Working Capital
101
162
151
97
222
233
543
581
575
512
964
890
- -
LT Debt
41
34
44
61
74
256
284
325
500
532
545
608
646
Total Equity
- -
19.88
28.79
35.08
28.38
16.92
11.76
11.09
19.63
12.91
7.11
8.24
21.44
Return on Invested Capital (%)
- -
4.57
10.51
38.55
33.31
21.46
13.76
11.56
23.86
15.09
7.86
10.33
30.72
Return on Capital (%)
- -
-0.19
35.9
156.47
186.43
83.4
44.4
40.5
67.31
33.52
15.02
25.06
23.22
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
- -
85
- -
LT Borrowings
- -
911
- -
LT Finance Leases
- -
14
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
1,972
1,803
1,811

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
630
663
643
Cash, Cash Equivalents & STI
118
166
150
Accounts Receivable, Net
129
118
130
Inventories
351
350
340
Total Current Liabilities
307
360
293
Payables & Accruals
- -
- -
- -
ST Debt
- -
85
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
43.59%
17.71%
11.6%
Free Cash Flow
182.68%
34.22%
-8.29%
Net Income, GAAP
-2,026.64%
29.67%
82.44%
Sales/Revenue/Turnover
11.94%
11.1%
4%
Total Cash Common Dividend
- -
18.54%
-16.19%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
299
280
312
291
1,181
2025
302
272
295
306
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.81
0.32
- -
- -
2.11
2025
0.62
0.39
- -
0.84
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.88
2025
- -
- -
- -
- -
- -
Similar Companies
Solara Active Pharma Sciences Limited (SOLARA.NS)
Hypera S.A. (HYPMY)
ScinoPharm Taiwan, Ltd. (1789.TW)
Acreage Holdings, Inc. (ACRHF)
Parenteral Drugs (India) Ltd. (PDPL.NS)
Aurobindo Pharma Limited (AUROPHARMA.NS)
Business
Dermapharm Holding SE is a Germany-based pharmaceutical company that develops, manufactures, and markets branded generic and over-the-counter (OTC) medicines. The company offers a broad portfolio of more than 600 products across categories including dermatology (e.g., antifungal creams and psoriasis treatments), cough and cold remedies, pain relief medications, vitamins and supplements, ophthalmics, and gastrointestinal drugs; key brands include Mundipharma generics, Linola skincare line, and Verla-Pharm specialties. It operates primarily in Europe, with production facilities in Germany and sales networks in over 20 countries, targeting pharmacies, wholesalers, hospitals, and online retailers. Dermapharm Holding SE was founded in 1997 and is headquartered in Grünwald, near Munich, Germany. [ from previous][ from previous] In recent developments, the company completed the acquisition of Fougera Pharmaceuticals in 2023, significantly expanding its U.S. dermatology presence with topical generics, followed by strategic investments in production capacity at its German sites in 2024 to meet rising demand for OTC products. It announced a partnership with a leading European distributor in early 2025 to enhance market penetration in Eastern Europe and launched new formulations in its Linola brand for sensitive skin conditions. Additionally, Dermapharm reported strong revenue growth in its H1 2025 results, driven by e-commerce expansion and successful tender wins in hospital segments, with no major reorganizations or name changes noted.